18f-fdg PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: A meta-analysis

Acta Radiologica

Volumn 53, Issue 6, 2012, Pages 615-627

  Cheng, Xu ^a   Li, Yongjun ^a   Liu, Biao ^a   Xu, Zhaoqiang ^a   Bao, Lihua ^a   Wang, Jie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Fluorodeoxyglucose F18; Meta analysis; Neoadjuvant chemotherapy; PET; PET CT

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; ACCURACY STUDY; BREAST CANCER; COCHRANE DATABASE; CONFIDENCE INTERVAL; DIAGNOSTIC PERFORMANCE; FDG PET; FLUORODEOXYGLUCOSE; IMAGING METHOD; LIKELIHOOD RATIOS; MEDLINE; META-ANALYSIS; ODDS RATIOS; PATHOLOGICAL RESPONSE; POSITION EMISSION TOMOGRAPHY; QUALITY ASSESSMENT; RECEIVER OPERATING CHARACTERISTICS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMATIC REVIEW;

DISEASES; PATIENT TREATMENT; POLYETHYLENE TEREPHTHALATES;

CHEMOTHERAPY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; META ANALYSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RISK; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BREAST; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84864031130     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2012.110603     Document Type: Article

References (30)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85
3. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66
4. Skaane P, Young K, Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading-Oslo I study. Radiology 2003;229:877-84
5. Yuan Y, Chen XS, Liu SY, et al. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. Am J Roentgenol 2010;195:260-8
6. Cheng X, Li Y, Xu Z, et al. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis. Acta Radiol 2011;52:779-87
7. Cheng X, Li Y, Xu Z, et al. A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin Neurosci 2011;18:307-12
8. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006;6:9
9. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25
10. Park JS, Moon WK, Lyou CY, et al. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol 2011;52:21-8
11. Rousseau C, Devillers A, Campone M, et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 2011;38:1029-36
12. Schneider-Kolsky ME, Hart S, Fox J, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010;12:R37
13. Jung S-Y, Kim S-K, Nam B-H, et al. Prognostic Impact of [18F] FDG-PET in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol 2010;17:247-53
14. Martoni AA, Zamagni C, Quercia S, et al. Early 18F-2-fluoro-2-deoxy-d- glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 2010;116:805-13
15. Choi JH, Lim HI, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 2010;102:392-7
16. Duch J, Fuster D, Muñoz M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551-7
17. Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19:1347-57
18. Li D, Yao Q, Li L, et al. Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007;6:1442-8
19. Rousseau C, Devillers A, Sagan C, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography. J Clin Oncol 2006;24:5366-72
20. Prati R, Minami CA, Gornbein JA, et al. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 2009;115:1194-202
21. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-41
22. Berriolo-Riedinger A, Touzery C, Riedinger J-M, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915-24
23. Kim SJ. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7
24. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18) F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95
25. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88
26. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8
27. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31
28. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6
29. Tozaki M, Sakamoto M, Oyama Y, et al. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 2010;31:895-902
30. Uematsu T, Kasami M, Yuen S. Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol 2010;20:2315-22